title: Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.
abstract: Intravenous zanamivir is in clinical development for the treatment of influenza in hospitalized patients, many of whom have renal impairment. This open-label study evaluated zanamivir pharmacokinetics and clinical safety following a single 100-mg intravenous infusion dose in subjects with impaired renal function compared with normal renal function. Male and female subjects between 18 and 79 years of age were recruited, four subjects to each renal function group (normal function and mild, moderate, and severe impairment). Serial blood samples were collected up to 24 h after dose administration (48 h for the severe renal impairment group) to estimate zanamivir serum pharmacokinetic parameters. Urine was collected over the same 24-h (or 48-h) period for estimation of renal clearance (CLR). Zanamivir pharmacokinetics were assessed by regression analysis of systemic clearance (CL) and CLR as a function of creatinine clearance (CLCR). Safety evaluations included adverse-event monitoring, vital signs, electrocardiogram, and clinical laboratory assessments. Zanamivir clearance (total and renal) significantly decreased with decreasing renal function, with corresponding increases in area under the concentration-time curve and elimination half-life. Renal impairment had no apparent effects on peak concentration or volume of distribution. Regression analysis indicated that zanamivir clearance was highly correlated (r(2) = 0.89) with creatinine clearance: CL ≅ 7.08 + 0.826 · CLCR. There were no patterns or trends in adverse events, and no new safety concerns were identified following administration of intravenous zanamivir. Results from this study support the inclusion of subjects with renal impairment, with appropriate dose adjustment, in studies to evaluate intravenous zanamivir in the treatment of influenza.
authors.affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, USA. steve.2.weller@gsk.com
authors.forename: Stephen
authors.initials: S
authors.lastname: Weller
authors.forename: Lori S
authors.initials: LS
authors.lastname: Jones
authors.forename: Yu
authors.initials: Y
authors.lastname: Lou
authors.forename: Amanda
authors.initials: A
authors.lastname: Peppercorn
authors.forename: Judith
authors.initials: J
authors.lastname: Ng-Cashin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D003404:Creatinine / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D005260:Female; D006801:Humans; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D051437:Renal Insufficiency / Q000150:complications; D055815:Young Adult; D053243:Zanamivir / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000998:Antiviral Agents; D003404:Creatinine; D053243:Zanamivir